Sunnyou
Intelligent Rehabilitation Equipment R&D and Manufacturer
Neuralink
Brain-Computer Interface System Developer
BrainCo
Non-invasive brain-computer interface technology solution provider
In early 2026, the capital market saw the brain-computer interface sector completely ignited!
The A-share brain-computer interface concept sector has seen consecutive limit-up surges, sparking a capital frenzy, while overseas Neuralink officially announced the start of large-scale production of brain-computer interface devices. Immediately following, BrainCo, a domestic unicorn, just completed a massive 2 billion yuan financing round. Additionally, with the policy boost of China's seven departments including the inclusion of brain-computer interfaces in the "15th Five-Year Plan" and the establishment of independent pricing under medical insurance, the entire track’s capital enthusiasm has been pushed to its peak.
In this capital feast sweeping the market, a rising star in brain-computer interface from the rehabilitation medical device field — Sunnyou. As the leading company in China's rehabilitation device industry, Sunnyou has successfully taken its place at the forefront thanks to its forward-looking layout in brain-computer interface.Since betting on brain-computer interfaces in September 2024, the stock price has surged nearly 200%, finally gaining recognition from the capital market.
Notably, just yesterday (January 13), Sunnyou Medical's single-day margin financing purchases reached 170 million yuan, with the margin financing balance surpassing 325 million yuan.
When the market is going crazy about the future of brain-computer interfaces, why is Sunnyou able to stand out? Behind the capital's enthusiasm, is it truly supported by hardcore technology and implementation capabilities, or is it simply following the trend?
▲Stock Price Trend Chart of Sunnyou Since Its IPO
丨From Stock Price Roller Coaster to Brain-Computer Interface "Soaring High"
Sunnyou Medical, established in 2002, successfully landed on the STAR Market in 2021 and is a China-based rehabilitation company.Medical Device IndustryA leading enterprise. Focused on rehabilitation fields such as pain, neurology, orthopedics, postpartum, post-surgery, cardiopulmonary, traditional Chinese medicine, elderly care, and the integration of medical and elderly care, providing a series of rehabilitation products and comprehensive solutions for medical, elderly care, and disabled persons' federations institutions at all levels across China, as well as for families.
The performance fluctuations of Sunnyou Medical in recent years are almost a microcosm of the development of China's rehabilitation device industry.
Sharing Industry Bonuses, Performance Soaring Rapidly
Sunnyou Seized Industry Opportunities from 2017 to 2020. Total revenue increased from 289 million yuan to 496 million yuan, with an annual compound growth rate of 19.73%; Net profit attributable to parent company soared from 64 million yuan to 196 million yuan, reflecting an annual compound growth rate as high as 44.86%. The growth was mainly driven by the company's continuous promotion of product innovation, with comprehensive growth achieved across its four major business segments—Rehabilitation Therapy, Rehabilitation Training, Rehabilitation Assessment, and Operating Accessories.
High growth in performance is also reflected in the capital market. After Sunnyou Medical's IPO in March 2021 until the end of June the same year, its stock price surged by approximately 320%, with its market value rapidly increasing from 7.2 billion yuan to 19.2 billion yuan.
"Special Period" Hits, Continuous Pressure on Performance
From 2021 to 2022, the company's growth momentum slowed significantly due to factors such as the postponement of medical institution procurement and disruptions in marketing and logistics caused by the "special period."
Sunnyou's total revenue growth rate dropped from 5.65% to -6.68%, and the growth rate of net profit attributable to parent company dropped from 2.87% to -37.85%.
Demand Recovers and Then Fluctuates, R&D Investment "Drags" on Short-Term Profits
In 2023, terminal demand rebounded, and Sunnyou Medical's performance strongly recovered, with revenue reaching 745 million yuan, a year-on-year increase of 52.46%; net profit attributable to shareholders was 227 million yuan, surging by 81.03%. This marked a significant growth in both total revenue and net profit attributable to shareholders.
However, the growth rate of net profit attributable to parent company shareholders once again declined from 2024 to the first half of 2025 — the core reason being that the company heavily invested in establishing a rehabilitation robot laboratory and preparing for the Sun-BCI Lab brain science laboratory, among others, to explore cutting-edge fields such as brain-computer interfaces and rehabilitation robots, resulting in a significant increase in R&D personnel and related expenses.
Notably, despite fluctuations in performance, Sunnyou remains a "high dividend payer": with a total of 277 million yuan distributed since its IPO, and the cumulative cash dividends over the past three years divided by the average annual net profit attributable to shareholders reaching 219.9%, demonstrating solid cash flow.
Notably, Wis Medical, a peer competitor, is also mired in a growth trough. Clearly, sharp fluctuations in performance might be a typical characteristic of an emerging industry grappling with macro-environmental changes and waves of technological innovation.
It is precisely because of betting on rehabilitation robots, a new future direction for rehabilitation, that although Sunnyou Medical's short-term profits have been pressured due to a sharp increase in R&D expenses, its stock price has risen against the market trend due to the market's reevaluation of its long-term technological prospects: since late September 2024, its stock price has surged nearly 200% at its highest point.
Sunnyou's forward-looking and active layout in the new track of future rehabilitation precisely demonstrates that, in a technology-drivenMedical DeviceIn the industry, continuous and bold R&D investment is the key to supporting long-term valuation. Based on the track dividend, Sunnyou has achieved a dual-line layout for growth. By accurately tapping into the brain-computer interface trend, Sunnyou has managed to break free from the fate of performance fluctuations and realized a valuation leap. The core lies in relying on the broad dividends of the rehabilitation track, strengthening its foundation through short-term transformation, and achieving long-term technological breakthroughs with a dual-line strategy, thus forming a competitive advantage.
In recent years, the continuous intensification of population aging has led to a surge in demand for rehabilitation medical services; in 2024, the population aged 65 and above in China reached 220 million, accounting for 15.6%. This, combined with the urgent need for "machine replacement of humans" due to the expanding gap in professional nursing staff, has turned niche sectors such as rehabilitation robots into blue ocean markets. Data predicts that the market size of rehabilitation medical devices in China will increase from 51.1 billion yuan in 2022 to 94.2 billion yuan in 2026, with an annual compound growth rate of 16.5%.
In the short term, Sunnyou's product structure is undergoing a transformation.
Upgrading from single-device sales to a comprehensive model of "Device + Solution + Service" to assist in building a "Six-All" smart health care and rehabilitation system to bind customers and break away from price wars; at the same time, actively exploring out-of-hospital home markets and overseas businesses. Currently, products have been sold to more than 30 countries and regions including Southeast Asia and the Middle East, obtaining EU CE certification and winning multiple national registration certificates. Although the current proportion of overseas income is less than 2%, the growth potential is enormous.
In addition, the company's inspection and testing center has obtained CMA and CNAS qualification certifications, filling the gap in the full industrial chain testing of rehabilitation equipment in China, and generating additional revenue from over 700 new testing services.
In the long term, Sunnyou actively explores cutting-edge technology fields such as brain-computer interfaces and rehabilitation robots.
In the field of brain-computer interfaces, the focus is primarily on non-invasive technologies, with key directions including mental health, motor imagery, and active training. This encompasses the development of five major product systems: EEG acquisition devices, brain-controlled products, lifestyle scenario products, proprietary algorithms, and brain biomedical research. Among these, core products such as electroencephalographs are expected to receive certification successively by the second half of 2025. Additionally, significant research efforts will target equipment for neurofeedback, cognitive screening, sleep disorder intervention, and neonatal EEG monitoring.
▲Sunnyou Medical Partial Brain-Computer Interface Product Diagram (Image Source: Guosheng Securities Research Report)
In terms of robot layout, Sunnyou focuses on six key areas—movement, physiotherapy, balance, assessment, nursing, and brain-computer interface—to develop medical-grade rehabilitation robots. Currently, the TCM moxibustion robot and infrared light moxibustion robot have obtained registration certificates. It is expected that by 2025, seven more products will receive certification, with around ten prototypes to be launched.
丨After the Concept Carnival, Value Delivery is the Key
Obviously, Sunnyou's "value success" in a certain sense does have its highlights in terms of industry dividends and technology layout, both in the short term and in the long run.
But it usually takes more than five years for medical devices to go from development to certification, with the registration of Class III devices alone requiring 3-4 years. From obtaining certification to reaching significant sales volumes, it takes another 3-5 years. Several key products of the company are expected to obtain certifications one after another in the second half of 2025, with large-scale clinical applications starting after 2026.
The current rise in stock prices is mainly driven by the hype around brain-computer interfaces. The leap from "concept" to "value" depends on whether the products can truly be implemented, widely accepted by the market, and translated into financial performance. If short-term product sales performance does not promptly reflect in the financial reports, market patience may be tested.
Amid the waves of aging and technological change, whether Sunnyou can balance long-term investment with short-term performance, successfully navigate through the transition pains, and achieve a leap in technological dividends remains to be seen.